Effects of Shugan Yipi granules combined with Recombinant Human Interferon α2b for Injection in treatment of patients with chronic hepatitis B
Objective:To observe effects of Shugan Yipi granules combined with Recombinant Human Interferon α2b for Injection in treatment of patients with chronic hepatitis B.Methods:A prospective study was conducted on 86 patients with chronic hepatitis B admitted to the hospital from June 2020 to June 2023.According to the random number table method,they were divided into study group and control group,43 cases in each group.The control group was treated with Recombinant Human Interferon α2b for Injection,while the study group was treated with Shugan Yipi granules on the basis of that of the control group.The total effective rate,the hepatitis B virus deoxyribonucleic acid(HBV-DNA)negative conversion rate,the liver function indexes[serum alanine aminotransferase(ALT),total bilirubin,aspartate aminotransferase(AST)and albumin]levels,the liver fibrosis indexes[serum type IV collagen(C-IV),laminin(LN)and hyaluronic acid]levels,the inflammatory indexes[serum C-reactive protein(CRP),procalcitonin]levels,the T cell subgroup indexes(CD3+,CD4+)levels,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the study group was 95.35%,which was higher than 79.07%in the control group,and the difference was statistically significant(P<0.05).The HBV-DNA negative conversion rate in the study group was 93.02%,which was significantly higher than 74.42%in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of serum albumin,CD3+and CD4+in the study group were higher than those in the control group;the serum ALT,total bilirubin,AST,C-IV,LN,hyaluronic acid,CRP and procalcitonin levels were lower than those in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Shugan Yipi granules combined with Recombinant Human Interferon α2b for Injection in the treatment of the patients with chronic hepatitis B can improve the total effective rate of treatment,the HBV-DNA negative rate,the CD3+and CD4+levels,improve the levels of liver function indexes,and reduce the levels of liver fibrosis indexes and inflammatory indexes.Moreover,it is superior to single Recombinant Human Interferon α2b for Injection treatment.
Shugan Yipi granulesRecombinant Human Interferon α2b for InjectionChronic hepatitis BLiver fibrosisLiver functionT cell subset
NETL
NSTL
万方数据
